HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2025. Filed Mar 13, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 13, 2026
HBIO$9.09+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| HARVARD BIOSCIENCE, INC. | ||
|---|---|---|
| CONSOLIDATED STATEMENTS OF OPERATIONS | ||
| (In thousands, except per share data) | ||
| Year Ended December 31, | ||
| 2025 | 2024 | |
| Revenues | $86,550 | $94,135 |
| Cost of revenues | 36,640 | 39,369 |
| Gross profit | 49,910 | 54,766 |
| Sales and marketing expenses | 19,216 | 22,212 |
| General and administrative expenses | 17,742 | 21,493 |
| Research and development expenses | 8,825 | 10,406 |
| Amortization of acquired intangible assets | 4,027 | 5,255 |
| Goodwill impairment - Note 5 | 47,951 | - |
| Other operating expenses - Note 2 | 729 | 1,611 |
| Total operating expenses | 98,490 | 60,977 |
| Operating loss | (48,580) | (6,211) |
| Other expense: | ||
| Interest expense | (4,917) | (3,536) |
| Loss on pension settlement - Note 8 | (1,233) | - |
| Loss on equity securities - Note 12 | - | (1,593) |
| Other expense, net | (2,656) | (325) |
| Total other expense | (8,806) | (5,454) |
| Loss before income taxes | (57,386) | (11,665) |
| Income tax (benefit) expense | (686) | 740 |
| Net loss | $(56,700) | $(12,405) |
| Loss per share: | ||
| Basic and diluted loss per share | $(1.28) | $(0.28) |
| Weighted-average common shares: | ||
| Basic and diluted | 44,391 | 43,538 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.